For neurologists & MS care teams
Manage your MS patients
between every
appointment.
DMT adherence, relapse patterns, fatigue trends, walking data, and patient-reported outcomes - so your team sees the full picture before every visit, not a symptom summary recalled under pressure every few months.
HIPAA compliant · EHR integration · RTM billing eligible · Wearable & Tenovi device support
Integrates with
EpicCernerathenahealtheClinicalWorksMEDITECHNextGen
Why continuous monitoring changes MS outcomes
Relapses build silently between visits.
Daily data shows what's actually happening.
Simple enrolment
From referral to monitored patient
in under a week.
DMT adherence tracking and daily symptom logging start immediately. No device required to begin. Optional Tenovi smart pillbox ships pre-paired for oral DMT tracking. Wearable integration adds walking and fatigue data automatically.
1
Set DMT schedule and monitoring parameters
Enter DMT name, formulation (injectable, oral, or infusion cycle), dosing schedule, and alert thresholds. Set relapse symptom domains to watch. Under 3 minutes in the portal.
2
Patient onboards via Ziva app
Isabella walks the patient through their DMT schedule and daily symptom check-in. Designed for ease - works well even on high-fatigue days. Voice logging available for patients with hand or vision limitations.
3
Daily symptom and walking data stream in
Fatigue severity, new neurological symptoms, pain, bladder function, and mood - logged daily. Wearable step count and gait metrics stream automatically. Your portal updates in real time.
4
Isabella flags relapse signals early
Isabella builds a personalised relapse signature per patient - the combination of fatigue, walking decline, new symptom domains, and DMT gaps that precede their relapses. Alerts your team when the pattern re-emerges.
5
Monthly RTM report compiled automatically
DMT adherence, relapse log, fatigue and walking trends, patient-reported outcomes, and Isabella's clinical notes - auto-attached to your EHR before every visit. Supports RTM billing documentation.
What Isabella tracks for MS patients
💊 DMT adherence — all formulations
Every dose timestamped against schedule for oral and injectable DMTs. Infusion cycle tracking for natalizumab and ocrelizumab. Tenovi smart pillbox for oral DMT auto-detection. Missed doses flagged and correlated with relapse onset.
⚡ Fatigue & symptom logs
Daily fatigue severity (0–10), new neurological symptoms by domain (visual, motor, sensory, bladder), pain score, cognitive difficulty, and heat sensitivity - all timestamped and correlated with DMT history.
🚶 Walking & mobility ⌚
Daily step count, gait cadence, and walking speed from wearable - tracked against each patient's personal baseline. Sustained walking decline is a sensitive early indicator of motor relapse or disease progression.
📊 Relapse pattern recognition
Isabella builds a personalised relapse signature per patient and alerts your team when the pattern emerges. Each relapse is logged with preceding signals, symptom domains, and severity - building a richer history over time.
Sophie A., 34* — RRMS
Relapse signal
Fatigue severity — last 4 weeks
3/10
4/10
6/10
8/10
Wk 1–2: controlledThis week: severe ⚠
DMT adherence this month74% ↓
New symptomsVisual (L eye) ×1
Walking speed vs. baseline ⌚↓ 18%
Sleep qualityDisrupted ×4
Routine days completed20 of 30 ✓
Isabella · Clinical summary
"Sophie's current pattern matches her previous 2 relapses: fatigue spiking over 5+ days, new visual symptom, walking speed declining significantly from her baseline, and DMT doses missed. Her prior relapses required IV methylprednisolone within 7 days. Early intervention window is now. Recommend urgent neurological review and MRI consideration. 20 routine days — RTM 98977 eligible."
Clinical dashboard
See relapses building.
Intervene before damage sets in.
Between appointments, relapses build and resolve - often partially - without your visibility. Ziva gives you the continuous picture: DMT adherence, fatigue trends, walking data, and new symptom flags, correlated against each patient's personal history, so you can intervene in the early window when treatment is most effective.
✓DMT adherence log — every dose timestamped, all formulations supported, missed doses flagged in real time
✓Personalised relapse signatures — Isabella builds each patient's unique early warning pattern from their own history
✓Walking speed monitoring — daily wearable gait data tracked against personal baseline, sustained decline flagged
✓New symptom domain logging — visual, motor, sensory, bladder, cognitive — each tagged with date and severity
✓Fatigue trends — daily severity 0–10, correlated with heat exposure, sleep, and prior relapse history
✓DMT response tracking — fatigue, walking, and relapse frequency over 6–12 months to assess treatment effectiveness
*Stories are inspired by real patient experiences and health patterns observed in care. Names, images, quotes, and certain details have been changed or combined to protect privacy. Individual experiences and outcomes may vary.
Ready to monitor your MS panel between appointments?
30-minute demo - DMT adherence dashboard, relapse alerts, RTM billing walkthrough.
RTM billing
MS qualifies for RTM
under musculoskeletal codes.
Multiple sclerosis qualifies for Remote Therapeutic Monitoring under CPT 98977 (musculoskeletal system). Ziva's daily symptom logs and medication check-ins generate the required data transmissions. New 2026 codes mean even patients with 2–15 engagement days are now billable.
Full engagement — 16–30 days / month
98975Initial setup & patient education (once)~$20 once
98977Device supply · musculoskeletal · 16–30 days/month~$40/mo
98980Treatment management · first 20 min~$50/mo
98981Treatment management · each additional 20 min~$45/mo
Partial engagement — 2–15 days / month (new 2026)
98985Device supply · 2–15 days/month~$40/mo
98979Treatment management · 10–19 min~$25/mo
Approximate Medicare rates. MS patients are often commercially insured - rates vary by payer. 98985 and 98977 are mutually exclusive per billing period. Consult your billing team.
RTM revenue estimate
MS patients on Ziva
20
5200
Engagement tier
Device supply — musculoskeletal (98977)$800/mo
Treatment management (98980)$850/mo
Add-on management (98981)$450/mo
Monthly RTM revenue estimate
$2,100
$25,200 annually
What drives RTM day count for MS
💊
Daily DMT log or pillbox event
Each medication check-in or smart pillbox detection is a timestamped data transmission - the most reliable daily signal for oral DMT tracking
⚡
Daily symptom check-in
Fatigue score, new symptom flag, pain, and bladder log - each daily check-in counts as a patient-reported data transmission day
⌚
Daily wearable sync
Step count, gait, and sleep data syncing daily from Apple Watch or Garmin - each day counts as a passive transmission toward the 16-day threshold
Illustrative only. Approximate Medicare rates. Consult your billing team before go-live.
Book a demo
See Ziva in action with
your MS panel.
30 minutes. DMT adherence dashboard, relapse alert walkthrough, wearable integration demo, RTM billing documentation, and a pilot design for your neurology practice.
✓Live walkthrough of DMT adherence dashboard and relapse pattern alerts
✓Wearable integration demo — how walking speed and gait data feed into the relapse signal
✓Monthly report format and RTM billing documentation walkthrough
✓EHR integration overview and pilot cohort design for your neurology practice
Other conditions
Request a 30-minute demo
We'll walk through enrolment, alert configuration, and the revenue model for your practice.
Book my demo →No commitment. We'll follow up within 1–2 business days.
Questions
Provider FAQ
MS qualifies under musculoskeletal RTM codes. CPT 98977 covers device supply for 16+ days per month. CPT 98985 (new 2026) covers 2–15 days. CPT 98980 covers the first 20 minutes of treatment management per month, and 98981 covers each additional 20 minutes. CPT 98975 is billed once for initial setup. Consult your billing team for payer-specific documentation requirements.
Injectable DMTs (interferon beta, glatiramer acetate) are tracked via daily app logging with optional photo confirmation. Oral DMTs (dimethyl fumarate, fingolimod, teriflunomide, siponimod) can be tracked via app or Tenovi smart pillbox for automatic detection. Infusion DMTs (natalizumab, ocrelizumab, alemtuzumab) are tracked by infusion cycle - your team logs infusion dates in the portal and Isabella monitors the inter-infusion period for symptom changes and adherence concerns.
Isabella analyses each patient's symptom history over time - identifying the combination of signals that consistently precede their relapses. For most RRMS patients this includes fatigue severity increasing over 3+ days, walking speed declining from baseline, sleep quality dropping, a new or worsening symptom in a specific domain (visual, motor, sensory), and often a recent missed DMT dose. When the same pattern re-emerges, Isabella alerts your team - typically 2–5 days before the patient would report a full relapse.
Apple Watch (Series 4+), Garmin, Oura Ring, and Fitbit - connected via Apple Health or Google Fit. Ziva uses step count, gait cadence, and walking pace data as the core mobility signals. A meaningful walking speed decline (typically >15% from personal 30-day baseline sustained over 3+ days) is the threshold for a mobility alert. Ziva works without a wearable; DMT adherence, symptom logs, and relapse pattern recognition are all available from the app alone.
Yes - Ziva supports RRMS, SPMS, and PPMS. For progressive subtypes where discrete relapses are less frequent, Isabella shifts focus toward trend monitoring: slow walking decline over months, fatigue trajectory, symptom domain spread, and quality of life scores over time. Monitoring parameters and alert thresholds are customisable per patient and MS subtype in the provider portal.
Yes. Fully HIPAA compliant, BAA available. All PHI encrypted in transit and at rest. US data residency. Security documentation and DPA available for your compliance team.